

Intercell AG

Notice

The following data represent a snapshot taken at the time of the initial public offering / new listing / inclusion in the MTF and are not updated regularly.

ISIN:	AT0000612601	
Symbol:	ICLL	
Trading segment:	Official Market	
Market segment:	prime market	
First day of trading:	February 28, 2005	
Offered shares:	up to 8,500,000 common stocks and up to 1,275,000 common stocks (Greenshoe)	
Category:	non-par-value bearer shares	
Number of shares (before IPO):	24,078,000	
Share capital (before IPO):	EUR 24,078,000	
Offering period:	from February 14, 2005 until February 25, 2005	
Price fixing:	The offering price was fixed and announced on February 25, 2005.	
Offer price:	EUR 5.50	
Issuing volume:	EUR 46,750,000,-- (excl. Greenshoe)	
Underwriting group:	Goldman Sachs International, Lehman Brothers, Bank Vontobel, DZ BANK, Erste Bank der oesterreichischen Sparkassen	
Management Board:	Dr. Alexander von Gabain, CEO Dr. Werner Lanthaler, CFO Dr. Gerd Zettlmeissl, COO Dr. Michael Joachim Buschle, CTO	
Supervisory Board:	Dr. Ernst Afting, Vorsitzender Michel Gréco, stellvertretender Vorsitzender Dr. Hans Albert Küpper Dr. Helmut Schühlsler Cathrin Petty Dr. David Ebsworth Dr. Luke Evnin Dr. Emilio Emini James Sulat	
Shareholder structure (before IPO not including own shares):	Apax Europe IV-A, L.P.	19.5%
	MPM Capital L.P.	16.2%
	Techno Venture Management GmbH	15.9%
	Nomura International plc	13.2%
	Kapital & Wert Vermögensverwaltung AG	9.8%
	NIBC Principal Instruments IV B.V.	6.2%
Address:	Intercell AG Campus Biocenter 2 A-1030 Vienna Phone: + 43 1 20620-0	

Internet: <http://www.intercell.com/>

Company profile: Intercell is a fast-growing biotechnology company with a clear strategy and focus on the design and development of novel vaccines for prophylactic and therapeutic treatment of diseases with substantial unmet needs. Since becoming operational in 1998, Intercell's mission is the discovery and development of innovative immunological products and technologies. Today, Intercell is one of the world's most promising young biotech companies. The company's unique proposition is based on the combination of antigens and Immunizers (adjuvants) proprietary technology platforms, as well as in-house GMP facilities. Intercell's technology has been endorsed by collaborative agreements with global pharmaceutical companies including Aventis, Merck&Co, Inc. and the Statens Serum Institute. Intercell has a broad development pipeline with a vaccine for Japanese Encephalitis, a vaccine for Hepatitis C undergoing phase II trials, and five products focused on infectious diseases in the pre-clinical phase, including a Pneumonia vaccine, a Group A Streptococcus vaccine and a traveler's diarrhea vaccine.